Metformin accelerates myelin recovery and ameliorates behavioral deficits in the animal model of multiple sclerosis via adjustment of AMPK/Nrf2/mTOR signaling and maintenance of endogenous oligodendrogenesis during brain self-repairing period
- PMID: 32048246
- DOI: 10.1007/s43440-019-00019-8
Metformin accelerates myelin recovery and ameliorates behavioral deficits in the animal model of multiple sclerosis via adjustment of AMPK/Nrf2/mTOR signaling and maintenance of endogenous oligodendrogenesis during brain self-repairing period
Abstract
Background: Multiple sclerosis (MS) is a devastating autoimmune disorder characterized by oligodendrocytes (OLGs) loss and demyelination. In this study, we have examined the effects of metformin (MET) on the oligodendrogenesis, redox signaling, apoptosis, and glial responses during a self-repairing period (1-week) in the animal model of MS.
Methods: For induction of demyelination, C57BL/6 J mice were fed a 0.2% cuprizone (CPZ) for 5 weeks. Thereafter, CPZ was removed for 1-week and molecular and behavioral changes were monitored in the presence or absence of MET (50 mg/kg body weight/day).
Results: MET remarkably increased the localization of precursor OLGs (NG2+/O4+ cells) and subsequently the renewal of mature OLGs (MOG+ cells) in the corpus callosum via AMPK/mammalian target of rapamycin (mTOR) pathway. Moreover, we observed a significant elevation in the antioxidant responses, especially in mature OLGs (MOG+/nuclear factor erythroid 2-related factor 2 (Nrf2+) cells) after MET intervention. MET also reduced brain apoptosis markers and lessened motor dysfunction in the open-field test. While MET was unable to decrease active astrogliosis (GFAP mRNA), it reduced microgliosis by down-regulation of Mac-3 mRNA a marker of pro-inflammatory microglia/macrophages. Molecular modeling studies, likewise, confirmed that MET exerts its effects via direct interaction with AMPK.
Conclusions: Altogether, our study reveals that MET effectively induces lesion reduction and elevated molecular processes that support myelin recovery via direct activation of AMPK and indirect regulation of AMPK/Nrf2/mTOR pathway in OLGs. These findings facilitate the development of new therapeutic strategies based on AMPK activation for MS in the near future.
Keywords: AMPK; Cuprizone; Multiple sclerosis; Nrf2; mTOR.
Similar articles
-
Metformin-induced AMPK activation stimulates remyelination through induction of neurotrophic factors, downregulation of NogoA and recruitment of Olig2+ precursor cells in the cuprizone murine model of multiple sclerosis.Daru. 2019 Dec;27(2):583-592. doi: 10.1007/s40199-019-00286-z. Epub 2019 Oct 16. Daru. 2019. PMID: 31620963 Free PMC article.
-
Low, but not high, dose triptolide controls neuroinflammation and improves behavioral deficits in toxic model of multiple sclerosis by dampening of NF-κB activation and acceleration of intrinsic myelin repair.Toxicol Appl Pharmacol. 2018 Mar 1;342:86-98. doi: 10.1016/j.taap.2018.01.023. Epub 2018 Jan 31. Toxicol Appl Pharmacol. 2018. PMID: 29407366
-
Metformin Therapy Attenuates Pro-inflammatory Microglia by Inhibiting NF-κB in Cuprizone Demyelinating Mouse Model of Multiple Sclerosis.Neurotox Res. 2021 Dec;39(6):1732-1746. doi: 10.1007/s12640-021-00417-y. Epub 2021 Sep 27. Neurotox Res. 2021. PMID: 34570348
-
Nudging oligodendrocyte intrinsic signaling to remyelinate and repair: Estrogen receptor ligand effects.J Steroid Biochem Mol Biol. 2016 Jun;160:43-52. doi: 10.1016/j.jsbmb.2016.01.006. Epub 2016 Jan 14. J Steroid Biochem Mol Biol. 2016. PMID: 26776441 Free PMC article. Review.
-
Signaling mechanisms involved in the regulation of remyelination in multiple sclerosis: a mini review.J Mol Med (Berl). 2023 Jun;101(6):637-644. doi: 10.1007/s00109-023-02312-9. Epub 2023 Apr 21. J Mol Med (Berl). 2023. PMID: 37084092 Review.
Cited by
-
Brain Boron Level, DNA Content, and Myeloperoxidase Activity of Metformin-Treated Rats in Diabetes and Prostate Cancer Model.Biol Trace Elem Res. 2022 Mar;200(3):1164-1170. doi: 10.1007/s12011-021-02708-z. Epub 2021 Apr 15. Biol Trace Elem Res. 2022. PMID: 33860456
-
A metformin add-on clinical study in multiple sclerosis to evaluate brain remyelination and neurodegeneration (MACSiMiSE-BRAIN): study protocol for a multi-center randomized placebo controlled clinical trial.Front Immunol. 2024 Feb 21;15:1362629. doi: 10.3389/fimmu.2024.1362629. eCollection 2024. Front Immunol. 2024. PMID: 38680485 Free PMC article.
-
Metformin remodels the myelin landscape.Neural Regen Res. 2026 Mar 1;21(3):1120-1121. doi: 10.4103/NRR.NRR-D-24-01495. Epub 2025 Mar 25. Neural Regen Res. 2026. PMID: 40145996 Free PMC article. No abstract available.
-
The impact of aging and oxidative stress in metabolic and nervous system disorders: programmed cell death and molecular signal transduction crosstalk.Front Immunol. 2023 Nov 8;14:1273570. doi: 10.3389/fimmu.2023.1273570. eCollection 2023. Front Immunol. 2023. PMID: 38022638 Free PMC article. Review.
-
Metformin attenuates white matter injury and cognitive impairment induced by chronic cerebral hypoperfusion.J Cereb Blood Flow Metab. 2023 Nov;43(2_suppl):78-94. doi: 10.1177/0271678X231175189. Epub 2023 May 12. J Cereb Blood Flow Metab. 2023. PMID: 37177813 Free PMC article.
References
-
- Sanadgol N, Zahedani SS, Sharifzadeh M, Khalseh R, Barbari GR, Abdollahi M. Recent updates in imperative natural compounds for healthy brain and nerve function: a systematic review of implications for multiple sclerosis. Curr Drug Targets. 2017;18(13):1499–517. - PubMed
-
- Annibali V, Mechelli R, Romano S, Buscarinu MC, Fornasiero A, Umeton R, Ricigliano VA, Orzi F, Coccia EM, Salvetti M, Ristori G. IFN-β and multiple sclerosis: from etiology to therapy and back. Cytokine Growth Factor Rev. 2015;26(2):221–8. - PubMed
-
- Prantner D, Perkins DJ, Vogel SN. AMP-activated kinase (AMPK) promotes innate immunity and antiviral defense through modulation of stimulator of interferon genes (STING) signaling. J Biol Chem. 2017;292(1):292–304. - PubMed
-
- Meares GP, Qin H, Liu Y, Holdbrooks AT, Benveniste EN. AMP-activated protein kinase restricts IFN-gamma signaling. J Immunol. 2013;190(1):372–80. - PubMed
MeSH terms
Substances
LinkOut - more resources
Medical
Miscellaneous